Experience With the Use of a Novel Agent, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, for Posttransplant Anemia in Renal Transplant Recipients: A Case Report

•A novel agent “roxadustat,” an HIF-PHI, may be effective for PTA treatment in renal transplant recipients.•However, the use of HIF-PHI requires careful monitoring, as there are overshoot cases.•Iron administration may also cause a rapid increase in hemoglobin, so caution is required.•Complications need to be investigated with more cases in the future.